Recent Trends in Adult and Pediatric Antiretroviral Therapy Monitoring and Failure

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 90; no. 2; pp. 193 - 200
• Main Authors: Boettiger, David C., An, Vu Thien, Kumarasamy, Nagalingeswaran, Azwa, Iskandar, Sudjaritruk, Tavitiya, Truong, Khanh Huu, Avihingsanon, Anchalee, Ross, Jeremy, Kariminia, Azar
• Format: Journal Article
• Language: English
• Published: United States JAIDS Journal of Acquired Immune Deficiency Syndromes 01-06-2022; Lippincott Williams & Wilkins Ovid Technologies
• Subjects: Adult; Anti-HIV Agents - therapeutic use; Antiretroviral agents; Antiretroviral drugs; Antiretroviral therapy; CD4 antigen; CD4 Lymphocyte Count; Child; Drug therapy; Epidemiology; Failure; Guidelines; HIV; HIV Infections - drug therapy; HIV Infections - epidemiology; Human immunodeficiency virus; Humans; Inclusions; Monitoring; Pediatrics; Treatment Failure; Trends; Viral Load
• ISSN: 1525-4135; 1944-7884
• DOI: 10.1097/QAI.0000000000002931

To assess recent trends in the monitoring of antiretroviral therapy (ART) and detection of ART failure in adult and pediatric HIV clinics.
We used data collected from 21 adult and 17 pediatric sites (across 13 and 6 countries/territories, respectively) in the International Epidemiology Databases to Evaluate AIDS - Asia-Pacific cohort. ART failure was defined as viral, immune, or clinical consistent with WHO guidelines.
A total of 8567 adults and 6149 children contributed data. Frequency of CD4 count monitoring declined between 2010 and 2019 among adult sites (from 1.93 to 1.06 tests/person per year, a 45.1% decline) and pediatric sites (from 2.16 to 0.86 testsperson per year, a 60.2% decline), whereas rates of viral load monitoring remained relatively stable. The proportion of adult and pediatric treatment failure detected as immune failure declined (from 73.4% to 50.0% and from 45.8% to 23.1%, respectively), whereas the proportion of failure detected as viral failure increased (from 7.8% to 25.0% and from 45.8% to 76.9%, respectively). The proportion of ART failure detected as clinical failure remained stable among adult and pediatric sites. The largest shifts in ART monitoring and failure type occurred in lower middle-income countries.
Although viral failure in our Asian cohort now comprises a larger portion of ART failure than in prior years, the diagnostic characteristics of immune and clinical failure, and recommendations on their management, remain important inclusions for regional ART guidelines.